drugset / Trial / NCT01729819

Interventional Clinical Trial in Patients in Overactive Bladder With Nocturia in Women

NCT01729819

Phase 2 Completed 106 enrolled Ferring Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the trial is to investigate the efficacy of combining tolterodine and desmopressin compared with tolterodine monotherapy in the treatment of women with overactive bladder with nocturia in terms of reduction of nocturnal voids during 3 months of treatment

Timeline

Start
2013-01
Primary completion
2014-11
Completion
2014-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Desmopressin Peptide Oral
Background Tolterodine Small molecule

Indications